Title
APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway
Date Issued
12 March 2018
Access level
open access
Resource Type
journal article
Author(s)
Benchabane H.
Tiwari A.
Tian A.
Li B.
Thompson J.
Hyde A.
Sawyer L.
Jodoin J.
Santos E.
Lee L.
Coffey R.
Beauchamp R.
Williams C.
Kenworthy A.
Robbins D.
Ahmed Y.
Lee E.
vanderbilt University
Publisher(s)
Cell Press
Abstract
Adenomatous polyposis coli (APC) mutations cause Wnt pathway activation in human cancers. Current models for APC action emphasize its role in promoting β-catenin degradation downstream of Wnt receptors. Unexpectedly, we find that blocking Wnt receptor activity in APC-deficient cells inhibits Wnt signaling independently of Wnt ligand. We also show that inducible loss of APC is rapidly followed by Wnt receptor activation and increased β-catenin levels. In contrast, APC2 loss does not promote receptor activation. We show that APC exists in a complex with clathrin and that Wnt pathway activation in APC-deficient cells requires clathrin-mediated endocytosis. Finally, we demonstrate conservation of this mechanism in Drosophila intestinal stem cells. We propose a model in which APC and APC2 function to promote β-catenin degradation, and APC also acts as a molecular “gatekeeper” to block receptor activation via the clathrin pathway. In the absence of Wnt ligand, APC (as part of the destruction complex) maintains low cytoplasmic β-catenin. Saito-Diaz et al. show that APC regulates not only β-catenin proteolysis, but also Wnt receptor activation. APC prevents constitutive activation of Wnt receptors in mammalian cells and Drosophila. APC loss results in ligand-independent pathway activation via clathrin-mediated endocytosis.
Start page
566
End page
581.e8
Volume
44
Issue
5
Language
English
OCDE Knowledge area
Biología del desarrollo
Scopus EID
2-s2.0-85042683098
PubMed ID
Source
Developmental Cell
ISSN of the container
15345807
Sponsor(s)
We thank Bloomington Drosophila Stock Center and Vienna Drosophila Research Center for Drosophila lines, the Vanderbilt Antibody and Protein Resource, and the Nikon Center of Excellence at Vanderbilt University. We thank Dr. Abel Alcazar-Roman for critical reading of this manuscript. This work was funded by NIH grants ( R01CA105038 , R01GM122222 , and R01121421 to Y.A.; NCIP5095103 Special Programs of Research Excellence in GI Cancer to R.J.C.; T32GM007347 and F30DK111107 to J.J.T.; R01DK099204 to C.S.W; CA069457 , GI SPORE P50CA095103 , and VICC P30CA068485 to R.D.B.; R01GM106720 to A.K.K.; R01GM081635 , R01GM103926 , and R35GM122516 to E.L.; P40OD018537 to the BDSC), the Norris Cotton Cancer Center (to Y.A.), a VA MERIT 2I01BX001426 (to C.S.W.), and two CTSA awards ( UL1TR000445 and UL1TR002243 ) from the National Center for Advancing Translational Sciences (to E.L.).
Sources of information: Directorio de Producción Científica Scopus